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ABSTRACT 
 
Familial Adenomatous Polyposis (FAP) is one of the most important clinical forms of 
inherited susceptibility to colorectal cancer, that is characterized by the development of 
hundreds to thousands of adenomas in the colon and rectum during the second decade 
of life. FAP is due to a germline mutation in the APC gene or to biallelic variations of 
MutYH gene. Almost all patients will develop cancer if the disease is not identified and 
surgically treated at an early stage. 
The aim of this study was to characterize, by peptidomic and genetic approaches, 4 pa-
tients that, although at the colonoscopy showed many polyps, they did not present any 
mutations of APC and MutYH genes (defined here unresolved FAP).  
Regarding the peptidomic study, MALDI-TOF analysis was performed on mutated and 
unresolved FAP patients. These data were compared with the one from adenoma pa-
tients, CRC patients and healthy control subjects. The peptide fingerprint of mutated 
FAP patients was obtained after performing statistical analysis. A subset of 45 ionic 
species was found differently expressed in the four groups considered, 12 of them pe-
culiar of FAP patients. Four ionic species were found significantly different in the 
switch between adenoma and malignant carcinoma. In this study, the potentially prog-
nostic peptides identified derive mainly from circulating proteins and some of them are 
involved in the inflammatory response. In particular, proteins such as Complement C3 
and C4 are known to be cleaved by exoproteases that seem pathology-related.  
In the case of unresolved FAP patients, in order to better define a specific pattern, the 
data from MALDI-TOF were combined with whole exome sequencing. The 
peptidomics data clearly mark a substantial difference between mutated and unresolved 
FAP patients. Indeed, unresolved FAP patients have characteristics similar to the con-
trol subjects, adenoma patients, CRC patients but not to mutated FAP patients. To un-
derstand the possible molecular pathway involved in the unresolved FAP cases, the 
whole exome sequencing (WES) was performed. From WES data analysis, 285 genes 
present in all the four unresolved FAP patients were filtered and selected. Among 
them, the O-linked glycans pathway of the mucins was the most represented.  
In conclusion, in this study it was defined for the first time a specific panel of peptides 
for mutated FAP patients, that could be useful to monitor and predict the pathological 
evolution of adenocarcinoma malignancy. Furthermore, it was possible to characterize 
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a preliminary genetic variations pattern for unresolved FAP patients, in which mucin 
genes might represent the key of the molecular pathway involved.  
However, further study are necessary to relate the identified mucin gene variations to 
their possible causative role in the polyposis. Future analysis of this pattern will be 
helpful, indeed, to better understand the interatome (the biological network that in-
cludes the whole set of direct and indirect molecular interactions in a cell) of these un-
resolved FAP patients. 
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RIASSUNTO 
 
La poliposi adenomatosa familiare (FAP) è una delle più importanti forme cliniche di 
cancro colo-rettale ereditario ed è caratterizzata dallo sviluppo di centinaia/migliaia di 
polipi adenomatosi nel colon e nel retto durante la seconda decade di vita. La FAP è 
causata da una mutazione germinale del gene APC o da varianti bialleliche del gene 
MutYH. Quasi tutti i pazienti FAP sviluppano il cancro se la patologia non viene pre-
cocemente identificata e trattata chirurgicamente.  
Lo scopo di questo lavoro è stato caratterizzare 4 pazienti in cui, nonostante l’esame 
colonscopico presentasse una poliposi conclamata, non risultavano mutazioni nei gene 
APC e MutYH (in questa tesi definiti pazienti FAP irrisolti) utilizzando un approccio 
integrato di peptidomica e genomica.  
Riguardo la peptidomica, il MALDI-TOF è stato utilizzato per studiare il profilo pepti-
dico plasmatico di pazienti FAP mutati ed irrisolti comparando i dati ottenuti con quelli 
derivanti dallo studio di pazienti con adenoma, cancro colo-rettale e soggetti sani di 
controllo. Dopo analisi statistica è stato ottenuto il fingerprint peptidico dei pazienti 
FAP mutati. Sono state ottenute 45 specie ioniche differentemente espresse nei quattro 
gruppi considerati, 12 delle quali peculiari per i pazienti FAP. L’intensità di segnale di 
quattro di queste specie ioniche è stata trovata statisticamente alterata nello switch tra 
adenoma e carcinoma maligno. I peptidi potenzialmente prognostici identificati in que-
sto studio derivano principalmente da proteine circolanti, alcune delle quali implicate 
nella risposta infiammatoria. In particolare è noto dalla letteratura che proteine del si-
stema del complemento come C3 e C4 vengono tagliate da esoproteasi che sembrano 
essere patologia correlate.  
Riguardo ai pazienti FAP irrisolti, per definirne un pattern specifico, i dati derivanti 
dall’analisi con il MALDI-TOF sono stati combinati con quelli ottenuti dal sequenzia-
mento dell’esoma. I dati di peptidomica hanno chiaramente evidenziato le differenze 
tra pazienti FAP mutati e FAP irrisolti. Infatti i pazienti FAP irrisolti presentano carat-
teristiche simili a quelle dei soggetti di controllo, dei pazienti con adenoma e cancro 
colo rettale ma non a quelle dei pazienti FAP mutati. Allo scopo di capire la via di tra-
sduzione del segnale implicata, è stato quindi eseguito il sequenziamento dell’esoma 
dei pazienti FAP irrisolti. Da questa analisi sono stati selezionati 285 geni variati in tut-
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ti i pazienti e tra questi la via di trasduzione del segnale della O-glicosilazione delle 
mucine è risultata la più rappresentata. 
In conclusione, in questo studio è stato definito per la prima volta un set peptidico spe-
cifico per i pazienti FAP mutati che potrebbe essere utilizzato per monitorare e predire 
l’evoluzione patologica della malattia. Inoltre è stato possibile caratterizzare un pattern 
preliminare per i pazienti FAP irrisolti in cui i geni delle mucine potrebbero rappresen-
tare la chiave della via di trasduzione del segnale implicata. Ulteriori studi saranno ne-
cessari per correlare i geni delle mucine con la poliposi e costruire l’interatoma 
(network biologico definito come l’insieme di tutte le interazioni molecolari dirette e 
indirette che ci sono all’interno di una cellula e di un organismo) di questi pazienti 
FAP irrisolti.  
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1. INTRODUCTION 
1.1. LARGE INTESTINE ANATOMY AND HISTOLOGY  
The large intestine is the terminal portion of the gastrointestinal tract (GI). The func-
tions of the large intestine are: the completion of absorption, the production of vita-
mins, the formation of feces, and the expulsion of feces from the body. 
The large intestine is about 1.5 m long and 6.5 cm in diameter and it extends from the 
ileum to the anus. Structurally, the four major regions of the large intestine are: the ce-
cum, colon, rectum, and anal canal (Figure 1, panel a). The opening from the ileum in-
to the large intestine is guarded by a fold of mucous membrane called the ileocecal 
sphincter (valve), which allows materials from the small intestine to pass into the large 
intestine. Hanging inferior to the ileocecal valve is the cecum, a small pouch about 6 
cm long. Attached to the cecum is a twisted, coiled tube, measuring about 8 cm in 
length, called the appendix. The open end of the cecum merges with a long tube called 
the colon, which is divided into ascending, transverse, descending, and sigmoid por-
tions. Both the ascending and descending colon are retroperitoneal; whereas the trans-
verse and sigmoid colon are not. The ascending colon ascends on the right side of the 
abdomen, reaches the inferior surface of the liver, and turns abruptly to the left to form 
the right colic (hepatic) flexure. The colon continues across the abdomen to the left 
side as the transverse colon. It curves beneath the inferior end of the spleen on the left 
side as the left colic (splenic) flexure and passes inferiorly to the level of the iliac crest 
as the descending colon. The sigmoid colon begins near the left iliac crest, projects 
medially to the midline, and terminates as the rectum at about the level of the third sa-
cral vertebra.  
The rectum, the last 20 cm of the GI tract, lies anterior to the sacrum and coccyx. The 
terminal 2–3 cm of the rectum is called the anal canal (Figure 1 panel b). The mucous 
membrane of the anal canal is arranged in longitudinal folds called anal columns that 
contain a network of arteries and veins. The opening of the anal canal to the exterior, 
called the anus, is guarded by an internal anal sphincter of smooth muscle (involun-
tary) and an external anal sphincter of skeletal muscle (voluntary). Normally these 
sphincters keep the anus closed except during the elimination of feces. 
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Figure 1: Anatomy of the large intestine. a: anterior view of the large intestine showing major re-
gions; b: frontal section of anal canal. (Tortora and Derrickson, 2009) 
 
The wall of the large intestine contains the typical four layers found in the rest of the 
GI tract: mucosa, submucosa, muscularis, and serosa. The mucosa consists of simple 
columnar epithelium, lamina propria, and muscularis mucosae (smooth muscle) (Fig-
ure 2 panel a). The epithelium contains mostly absorptive and goblet cells (Figure 2 
panel b and c). The absorptive cells function primarily in water absorption; the goblet 
cells secrete mucus that lubricates the passage of the colonic contents. The major com-
ponent of the mucus are the mucins. Mucins are filamentous high-molecular weight O-
glycosylated glycoproteins found mainly in mucous secretions, but present also in the 
cell surface acting as transmembrane glycoproteins with the glycan exposed to the ex-
ternal environment. The mucins in the mucous secretions can be large and polymeric 
(gel-forming mucins) or smaller and monomeric (soluble mucins). Mucins' key charac-
teristic is their ability to form gels; therefore they represent a key component in most of 
the gel-like secretions, having different functions such as the lubrication, the cell sig-
naling and the formation of chemical barriers. Due to this function, mucins are present 
in many epithelial surfaces of the body, including the gastrointestinal, genitourinary, 
and respiratory tracts, where they shield the epithelial surfaces from physical and 
chemical damage and protect against pathogens infection. 
Mature mucins present two distinct regions: the amino- and carboxy-terminal regions 
and the large central region rich in serine, threonine and proline residues. The first is 
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lightly glycosylated, but presents a high cysteines content, that causes the disulfide 
bonds between mucin monomers. The second one, the central region, is also called the 
variable number of tandem repeat region and can be highly O-glycosylated; about hun-
dreds of O-GalNAc glycans are need to reach the saturation of this region. The protec-
tive role of mucins is achieved by the presence of oxygen bond that attach the long 
sugar side-chains to the tandem repeat regions, avoiding the mucin degradation by the 
inhibition of protease activity and preserving the viscosity and density of the mucus 
(Molaei et al., 2010). The O-linked carbohydrates account for up to 80% of the molec-
ular weight of the mucins (Sheng et al., 2012). 
Up to now, 21 mucin genes have been described in literature. Among them, 15 are ex-
pressed in different regions of the gastrointestinal tract (Sheng et al., 2012) and are dis-
tinguished into secreted and cell surface mucins. In particular, among the 6 secreted 
mucins: five are oligomerizing secreted mucins (i.e. MUC2, MUC5AC, MUC5B, 
MUC6, MUC19) and one is a non-oligomerizing secreted mucin (i.e. MUC7). Except 
MUC19, the secreted mucins share a common evolutionary ancestor and are situated as 
a cluster on the chromosome 11p15.5. MUC2 is the predominant mucin produced by 
the intestinal goblet cells, whereas MUC5B is expressed in lower quantities by a subset 
of the goblet cells residing at the bottom of the colonic cryptic. There are nine genes 
encoding the major cell surface mucins in the intestine: MUC1, MUC3A, MUC3B, 
MUC4, MUC12, MUC13, MUC15, MUC16 and MUC17. Intestinal cell surface mucins 
are highly expressed in enterocytes.  
The mucin genes, their transcripts, the resulting mucin proteins and the attached O-
GalNAc glycans show all an extreme variability. Different mucins show changes in the 
number and composition of the peptide repeats in their VNTR regions, whereas in the 
same mucin the repeats usually vary in their amino acid sequences.  
Both absorptive and goblet cells are located in long, straight, tubular intestinal glands 
(crypts of Lieberkühn). Solitary lymphatic nodules are also found in the lamina propria 
of the mucosa and may extend through the muscularis mucosae into the submucosa. 
Compared to the small intestine, the mucosa of the large intestine does not have many 
structural adaptations that increase surface area.  
The submucosa of the large intestine consists of areolar connective tissue. The 
muscularis consists of an external layer of longitudinal smooth muscle and an internal 
layer of circular smooth muscle. Unlike other parts of the GI tract, portions of the lon-
gitudinal muscles are thickened, forming three conspicuous bands called the teniae coli 
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that cover most of the length of the large intestine (Figure 2 panel a). The teniae coli 
are separated by portions of the wall with less or no longitudinal muscle. Tonic con-
tractions of the bands gather the colon into a series of pouches called haustra which 
give the colon a puckered appearance. A single layer of circular smooth muscle lies be-
tween teniae coli. The serosa of the large intestine is part of the visceral peritoneum. 
Small pouches of visceral peritoneum filled with fat are attached to teniae coli and are 
called omental (fatty) appendices (Tortora and Derrickson, 2009). 
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Figure 2: Histology of the large intestine. a: three-dimensional view of layer of the large intestine; 
b: sectional view of intestinal glands and cell types; c: portion of the wall of the large intestine; d: 
details of mucosa of large intestine (Tortora and Derrickson, 2009). 
 
1.2. COLORECTAL CANCER (CRC) 
1.2.1. Epidemiology of CRC 
Incidence and mortality rates of CRC vary markedly around the world. It has been es-
timated that 93,090 cases of colon cancer and 39,610 cases of rectal cancer will be di-
agnosed in 2015 (American Cancer Society: Cancer Facts and Figures 2015. Atlanta, 
Ga: American Cancer Society, 2015). CRC is the third most common cancer in both 
men and women. However, the incidence rates have been decreased during the past 
two decades due to changes in the risk factors and to the preventive screening among 
adults 50 years and older. CRC screening tests allow, indeed, the detection and the re-
moval of colorectal polyps before they progress to cancer. From 2007 to 2011, the in-
cidence rates declined by 4.3% per year among adults 50 years of age and older, but 
increased by 1.8% per year among adults younger than age 50. An estimated 49,700 
deaths from colorectal cancer are expected to occur in 2015. CRC is the third leading 
cause of cancer death in both men and women and the second leading cause of cancer 
death when men and women are combined. From 2007 to 2011, the overall death rate 
declined by 2.5% per year. This trend reflects the declining incidence rates and the im-
provements in the early detection and treatment.  
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1.2.2. Risk and protective factors 
Early CRC stages typically does not have symptoms, that is why preventive screening 
is usually necessary to detect this cancer early. Symptoms may include rectal bleeding, 
blood in the stools, a change in bowel habits or stools shape (e.g., narrower than usual), 
the feeling that the bowel is not completely empty, cramping pain in the lower abdo-
men, decreased appetite, or weight loss. In some cases, blood loss from the cancer 
leads to anemia, causing symptoms such as weakness and excessive fatigue. Timely 
evaluation of symptoms consistent with CRC is essential, even for adults younger than 
age 50, among whom CRC is rare, but increasing.  
The risk of CRC increases with age; in 2011, 90% of cases were diagnosed in individ-
uals 50 years of age and older. Modifiable factors associated with increased risk in-
clude obesity; physical inactivity; moderate to heavy alcohol consumption; long-term 
smoking; high consumption of red or processed meat; low calcium intake; and very 
low intake of whole-grain fiber, fruit, and vegetables.  
Hereditary and medical factors that increase the risk include a personal or family histo-
ry of CRC and/or polyps, a personal history of chronic inflammatory bowel disease 
(e.g., ulcerative colitis or Crohn disease), certain inherited genetic conditions (e.g., 
Lynch syndrome, also known as Hereditary Nonpolyposis Colorectal Cancer 
(HNPCC), type 2 diabete and Familial Adenomatous Polyposis (FAP)).  
A large number of factors have been reported to be associated with a decreased risk of 
CRC. These include regular physical activity, a variety of dietary factors, the regular 
use of aspirin or nonsteroidal anti-inflammatory drugs (NSAIDs), and hormone re-
placement therapy in postmenopausal women. Regular use of aspirin and other 
NSAIDs are associated with a 20 to 40 percent reduction in the risk of colonic adeno-
mas and CRC in individuals at average risk. How the aspirin produce this protective 
factor is not well understood yet. Proposed explanations include the increase and im-
pairment of tumour cell growth by inhibition of cyclooxygenase-2 (Wang et al., 2012).  
 
1.2.3.  Colorectal cancer progression 
In 1990, Fearon and Vogelstein (Fearon and Vogelstein, 1990) presented evidences for 
a multistep genetic model of the CRC formation. This model is based on the under-
standing that CRC is the result of mutations in some key genes, such as the inactivation 
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of tumour suppressor genes (TSG) and the activation of oncogenes. Furthermore, the 
accumulation of mutations occurs in a sequential manner, with mutations of some 
genes preceding the one of the others. This genetic paradigm is shown in Figure 3. As 
seen, there are two different pathways that lead to the formation of CRC. One way is 
through inactivation of the TSG, APC gene (Adenomatous Polyposis Coli) that ac-
counts for approximately 85% of all CRC and it is germline mutated in patients with 
Familial Adenomatous Polyposis (FAP). The other CRC development pathway is 
through the mutational inactivation of a protein family involved in DNA mismatch re-
pair (MMR), including MLH1, MSH2, and PMS2 genes. MMR genes mutation is 
found in approximately 15% of all sporadic CRC and is responsible for the HNPCC 
syndrome if present as germline mutation. 
 
 
Figure 3: The genetic paradigm of colorectal cancer. The formation of CRC requires the sequen-
tial mutation of several genes. This includes the inactivation of TSGs (in green) and activation of 
oncogenes (in red) (Hisamuddin and Yang, 2004).  
 
1.2. HEREDITARY FORMS OF CRC 
Among the various causes of CRC, approximately 75% can be attributed to sporadic 
disease, where there is no apparent predisposing aetiology. The remaining cases of 
CRC are accounted for familial incidences (15%) and inflammatory bowel disease 
(IBD, 1%) (Figure 4). Although some familial cases consist of well-described heredi-
tary CRC syndromes, including FAP (1%), HNPCC (5%), and the hereditary hamar-
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tomatous polyposis syndromes (<1%), the majority of familial disease has no clearly 
identifiable genetic aetiology (Hisamuddin and Yang, 2004). 
 
 
Figure 4: The distribution of CRC conditions in the population.  
 
1.3.1.  Familial Adenomatous Polyposis (FAP) 
FAP is an autosomal dominant disease that is classically characterized by the devel-
opment of hundreds to thousands of adenomas in the colon and rectum during the sec-
ond decade of life (Half et al., 2009). Almost all patients will develop cancer if they are 
not identified and treated at an early stage. Clinically FAP arises equally in both sexes 
(Half et al., 2009). About half of the FAP patients develops adenomas at 15 years of 
age and 95% at 35 years of age (Petersen et al., 1991). Generally cancer starts to de-
velop a decade after the appearance of the polyps. If the colon is intact the majority of 
the FAP patients develops CRC at the ages of 40-50 years. However, although un-
common, CRC can develop in children or in older people.  
Individuals with FAP can also develop a variety of extra-colonic gastrointestinal mani-
festations: fundic gland polyps of stomach; adenomatous polyps in duodenum and 
periampullary region and small bowel adenomas.  
Extra-intestinal manifestations are rarely malignant and include: cutaneous lesions, os-
teomas and dental abnormalities. The phenotypic variant, characterized by this extra-
intestinal manifestation, is called the Gardner Syndrome. Other extra-colonic malig-
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nancy associated with FAP disease are: congenital hypertrophy of the retinal pigment 
epithelium, desmoids, pancreatic mucinous adenocarcinomas, liver, brain and thyroid 
tumors.  
A less aggressive variant of FAP is the Attenuated Familial Adenomatous Polyposis 
(A-FAP); this variant is characterized by fewer colorectal adenomatous polyps (usually 
10 to 100), that in the later age evolves in adenoma (the average age of polyps diagno-
sis is 44 years old) and cancer (at the age of 56 years old) (Half et al., 2009). 
Most of the FAP patients have a familiar history of colorectal polyps and cancer, how-
ever 25-30% of them develop de novo without clinical or genetic evidence of FAP in 
family members (Bisgaard et al., 1994). 
FAP is a genetic disorder resulting from a mutation in the APC gene. The first evi-
dence of the FAP gene location was supported by Herrera and colleagues, that demon-
strated the presence of a constitutional deletion of chromosome 5q21 in a patient with 
Gardner Syndrome (Herrera et al., 1986). The following linkage analysis showed that 
5q21 chromosome markers were related to the development of FAP (Bodmer et al., 
1987). The gene responsible for FAP was identified in 1991 and was called APC gene 
(Kinzler et al., 1991). In adenomas and carcinomas developed in FAP patients, there is 
an evidence of the inactivation of the second copy of the APC gene (Levy et al., 1994).  
 
1.3.2. APC gene and protein function 
The APC gene is a tumor suppressor gene located on the long arm of the chromosome 
5 in the band q21. It contains 17 exons (15 coding exons) and it has a transcript length 
of 10,619 base pairs (Ensembl). APC gene encodes a large polypeptide of 2843 amino 
acids with a molecular weight of 311646 Da (Uniprot).  
The APC protein has multiple domains that mediate oligomerization as well as binding 
to a variety of intracellular protein and it is present in a variety of epithelial tissues, of-
ten in post-mitotic cells (Midgley et al., 1997). APC is a crucial member of the Wnt/β-
catenin signaling pathway, that is an important determinant of cell proliferation, differ-
entiation and apoptosis. Studies indicate that APC is involved in the regulation of a 
myriad of cellular functions including proliferation, differentiation, apoptosis, adhe-
sion, migration and chromosomal segregation (van Es et al., 2001). Furthermore, APC 
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regulates cytoskeletal proteins including F-actin and microtubules, controlling cell ad-
hesion, migration and mitosis.  
The Wnt/β-catenin signaling pathway is also essential in controlling intestinal epitheli-
al cell proliferation (Reya and Clevers, 2005). A model for Wnt signaling is depicted in 
Figure 5. Wnt, a secreted glycoprotein, interacts with two cell surface receptors, Friz-
zled (Fz) and the low-density lipoprotein receptor-related protein (LRP) (Bhanot et al., 
1996). In the absence of Wnt or in the presence of wild-type APC, β-catenin is seques-
tered in the cytoplasm in a complex that includes APC, axin, and glycogen synthase 
kinase-3β, where it is subjected to ubiquitin-mediated degradation (Reya and Clevers, 
2005). In the presence of Wnt, or absence of APC (as occurs in many colon cancer), β-
catenin is released from the complex. Free β-catenin is shuttled into the nucleus, where 
it binds the T-cell factor (TCF) and releases its repressors, CtBP and Groucho, activat-
ing the gene transcription (Behrens et al., 1996). Among the target genes stimulated by 
β-catenin/TCF complex, there are c-Myc and cyclin D, both essential for the progres-
sion of the cell cycle during proliferation (He et al., 1998). The importance of Wnt/β-
catenin pathway in the pathogenesis of CRC is further demonstrated by the observation 
that in the absence of APC mutation, CRC sometimes contains inactivating mutation of 
axin (Jin et al., 2003) (Webster et al., 2000) or activating mutation of β-catenin (Sparks 
et al., 1998).  
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Figure 5: The Wnt/β-catenin signaling pathway. βCat β-catenin; CtBP—C-terminal binding pro-
tein; Dsh—Disheveled; Fz—Frizzled; Gro—Groucho; GSK—Glycogen synthase kinase 3β; 
LRP—Low-density lipoprotein receptor-related protein; TCF—T-cell factor (Hisamuddin and 
Yang, 2004).  
 
Some studies indicate that the carboxyl terminal portion of APC binds cytoskeletal 
proteins. As a microtubule-associated protein, APC contributes to mitotic spindle for-
mation and function. Cells lacking APC are prone to defects during chromosomal seg-
regation (Fodde et al., 2001).  
1.3.3.  APC mutations 
Mutations in the APC gene are present in up to 85% of FAP patients and in over 80% 
of sporadic CRC cases. It has been shown that loss of heterozygosity (LOH) is the 
main mechanism by which APC becomes inactivated. More than 300 mutations are 
recognized as cause of FAP. Most of these mutations result in the truncated protein. 
More than 60% of APC mutations are found in the central region of the gene, that is 
known as the mutation cluster region (MCR) and results in the expression of carboxyl-
terminally truncated proteins. The MCR region coincides with the APC region that is 
important for the down-regulation of β-catenin. APC mutations in the first or last third 
20 
 
of the gene are associated with an attenuated polyposis with a late onset and a small 
number of polyps. Non neoplastic cells of FAP patients are expected to retain normal 
APC function due to the presence of one wild-type allele, regardless of the position of 
the mutation in the affected allele.  
 
1.3.4.  MutYH-associated Polyposis (MAP) 
Although the majority of FAP syndromes is attributed to germline mutations in the 
APC gene, a small number of familial cases of polyposis do not have any APC muta-
tions but shows germline mutations in the MutYH gene. MutYH mutation causes the at-
tenuated polyposis condition known as MutYH-associated Polyposis (MAP). It is 
recessively inherited and patients have either a homozygous or a compound heterozy-
gous germline mutations of the MutYH gene.  
The MutYH gene contains 16 exons (ensemble database) and it maps to chromosome 
1p32-34. It encodes a protein of 546 amino acid that has a molecular weight of 60069 
Da (uniprot database). This protein is a DNA glycosylase enzyme involved in the oxi-
dative DNA damage repair. The enzyme is involved in the base excision repair (BER) 
process and excises adenine bases from the DNA backbone at the sites where the ade-
nine was inappropriately paired with guanine, cytosine, or 8-oxo-7, 8-dihydroguanine 
(8-oxoG) during the DNA replication (Takao et al., 1999).  
 
1.3.5.  Genetic tests 
Nowadays, a number of genetic tests are available to test for APC germline mutations. 
Currently, the most commonly used is the direct sequencing of the APC gene. The mu-
tation detection rate, when the full gene sequencing is performed, is 70%. However, 
the large insertions and deletions, having a frequency of about 5%, need other assays 
(e.g. Multiplex Ligation-dependent Probe Amplification or MLPA). MUTYH mutations 
are responsible of the remaining cases. When the family's specific APC mutation is 
identified, genetic testing of all the first degree relatives should be performed. Parents 
of children at-risk should be informed that the genetic testing is recommended just be-
fore puberty or preferably in mid-adolescence. Familiar members that result negative 
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for a known mutation do not need further investigation or follow-up other than stand-
ard average-risk screening of the population.  
Genetic testing for MUTYH mutation has been recommended for all patients who have 
tens to hundreds of colorectal adenomas with no identified germline mutation in the 
APC gene and with a family history compatible with an autosomal recessive mode of 
inheritance. 
 
Nowadays, several approaches are available to study the cancer disease in the clinical 
field as the proteomic analysis and Whole Exome Sequencing (WES). The following 
two paragraphs will elucidate the use of these approaches in the clinical field. 
 
1.4. PROTEOME STUDY 
The proteome is the entire set of proteins produced by an organism at certain time or 
under defined conditions. The clinical proteomics focuses on the characterization of 
unique patterns of protein expression, or biomarkers, associated with specific diseases. 
Matrix-assisted laser desorption/ionization mass spectrometry (MALDI-MS) is one of 
the most widely used proteomic technology and it is usually coupled with the time of 
flight (TOF) ion analyzer. MALDI is an ionization technique widely employed for pro-
teins and peptides analysis. The sample is mixed with a saturated solution of a matrix 
and deposited onto a plate to allow it to dry. When a laser bean hits the sample there is 
a production of ions. The ions are sent to the analyzer that separate the ions according 
to their mass/charge (m/z) ratio on the basis of the time that the ion takes to go from 
the source to the detector (Figure 6). MALDI is a “soft” ionization technique that al-
lows a minimal fragmentation of peptides. Furthermore, it almost exclusively creates 
single charged ions, which mean that the m/z value represents a realistic measurement 
of the actual mass of the particles. 
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Figure 6: MALDI-TOF schematic representation. (Montana State University) 
 
In accordance with the technologies progress, an increased interest has been arisen for 
the dynamic nature of sub-proteome presented in the blood. In particular, circulating 
low molecular weight (LMW) peptidome seems to be a source of disease-specific bi-
omarkers. Indeed, peptides show better permeability between tissues and cell mem-
branes than the corresponding full-length proteins. Furthermore, tumor specific 
proteolytic cascades within the tissue can generate fragments that diffuse into the cir-
culatory system. Proteases are proteins that cleave amino acid sequences at precise po-
sitions and they participate both in the physiological and tumor processes. Tumor spe-
cific peptides are derived not only from a population of cancer cells but also from the 
microenvironment tissue surrounding the tumor cells. It also was proposed that some 
LMW peptide might be generated in the blood vessel by degradative proteases that are 
already present in the blood. (Figure 7) (Petricoin et al., 2006).  
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Figure 7: Different cascades of peptide generation and release into the circulatory system. Circu-
lating peptides could be shed and generate from all the cell types present in the tissue microenvi-
ronment. (Petricoin et al., 2006).  
 
1.5. WHOLE EXOME SEQUENCING (WES) 
Human genome comprises more or less 3 × 109 bases having coding and non-coding 
sequences. About 3×107 base pairs (1%, 30 Mb) of the genome are the coding se-
quences. The genome assembly from the Genome Reference Consortium 
(GRCh37.p10, Feb 2009) in Ensembl Genome Browser includes about 20000 protein-
coding genes, pseudogenes and non-coding genes (Rabbani et al., 2014). It is estimated 
that 85% of the disease-causing mutations are located in the coding and functional re-
gions of the genome. For this reason, the complete sequencing of the coding regions 
(exome) has the potential to find the causes of a large number of rare genetic disorders 
(mostly monogenic) and as well as the predisposing variants present in common dis-
eases and cancers.  
Monogenic disease (also called Mendelian disease) are caused by a single gene variant 
conforms to the Mendelian inheritance laws. Over 6000 Mendelian diseases have been 
identified, however, the pathogenic genes of about half of these diseases remain un-
known. Whole-exome sequencing (WES) can be used to perform NGS of exon-
enriched samples and to identify protein-coding mutations, including missense, non-
sense, splice site, and small deletion/insertion mutations. The application of WES defi-
nitely represents a revolutionary progress in Mendelian disease research (Zhang, 
2014). Indeed, one of the major advantage in the use of WES in Mendelian disorders is 
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that it requires a low amount of clinical cases, indeed only a small number of individu-
als for each family are necessary for the analyses. 
However, there is also an increased interest in leveraging the power of exome sequenc-
ing in diseases that do not exhibit a Mendelian mode of transmission (disease caused 
by non inherited or de novo mutations) and disease with a complex genetic component. 
WES technique could definitely help, at the clinical point of view, to understand the 
genetic mechanisms of the cancer formations and to find successful treatments. As 
mentioned in the literature, the first cancer exomes were sequenced soon after the 
completion of the Human Genome Project in 2001. Ley et al. used NGS to study the 
exomes of human acute myeloid leukemia (AML) cells in 2003 (Ley et al., 2003), 
whereas the first investigated solid tumor exomes derived from breast and colorectal 
cancer tissue samples (Sjoblom et al., 2006).  
Although a lot of progress has been made, the currently available NGS technologies, 
such as HiSeq™ (Illumina), SOLiD4™ (Life Technologies™), and 454 GS FLX 
(Roche), generate hundreds of millions of short sequence reads with an average length 
in the range of 50 bp to 125 bp. This technique, as consequence, presents a sequencing 
error rate higher than the Sanger sequencing; thus, further validation using Sanger se-
quencing is essential (Zhang, 2014). 
The three main steps of exome sequencing are:  
1) Exome enrichment;  
2) DNA high-throughput sequencing; 
3) Biological interpretation.  
Exome enrichment is the base of the exome sequencing. The genomic DNA is random-
ly sheared and used to form a shotgun library. The exome regions are enriched by hy-
bridization capture (using oligonucleotide probes to hybridize the fragments of inter-
est). The noncoding DNA sequences are then removed. After the sample preparation 
and sequencing, 20000 and 50000 variants are identified per sequenced exome. The 
disease-causing variants should be represented by the non-synonymous variants, splice 
acceptor-site or donor-site mutations, and insertions/deletions. Candidate variants are 
absent from the most databases of the known variant, such as dbSNP, and 1000 Ge-
nomes Project. Further specific candidate variants can be predicted by ANNOVAR or 
SIFT software tools. The predicted damaging variants can be sequenced by the tradi-
tional Sanger sequencing to confirm the real causative variant. 
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As in all the approaches, also WES analysis presents some limitations: it is known that 
approximately 85% of variants are in the coding exons, meaning that 15% are outside 
the exons, in the noncoding, conserved, or regulatory regions. Furthermore, some stud-
ies have revealed that 80% to 90% of the targeted regions are covered by more than 
10X, but 4-8 Mb (or 1000 to 2000 genes) have no sufficient coverage for variant detec-
tion. 
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2. MATHERIALS AND METHODS 
2.1. MUTATED and UNRESOLVED FAP PEPTIDOME 
2.1.1. Patients selection and plasma preparation  
All the sample were obtained from the Tissue Biobank at the First Clinical Surgery 
Section of the Department of Surgical, Oncological and Gastroenterological Science. 
Briefly, the plasma samples were collected from 13 mutated FAP patients (APC or 
MutYH mutated, see Table 4), 4 unresolved FAP patients (Table 7), 26 adenoma pa-
tients, 58 sporadic CRC patients and 38 control subjects resulted negative at the colon-
oscopy. A complete clinical history and written informed consent was obtained from 
each patient (Ethical Committee approval number 448). 
Blood samples were collected in DB Vacutainer® Blood Collection Tubes (Becton 
Dickinson and Company, Franklin Lake, NJ, USA) containing K3EDTA. Plasma was 
obtained after centrifugation for 10 mins at 3000 rpm and the aliquots were stored at -
80°C until further analysis, following the Biobank’s protocol. 
 
2.1.2. Sample preparation 
Plasma samples (200 microliters) were diluted 1:4 in deionized water and 500 µl of the 
solution were centrifuged for 20 mins at 3000 g in Amicon Ultra-4 Centrifugal Filter 
Devices with 30 KDa MWCO (molecular weight cut-off) (Millipore, Merck KGaA, 
Darmstadt, Germany). Before MALDI-TOF analysis, the concentrate was discarded 
from the filter unit sample to eliminate high molecular weight proteins and the eluate 
was desalted and purified by ZipTip C18 pipette tips (Millipore, Merck KGaA, Darm-
stadt, Germany) following the procedure described in the user’s guide. 
 
2.1.3. MALDI-TOF analysis 
Peptide profile analysis was performed using a Voyager-DE PRO instrument (Applied 
Biosystems, Foster City, CA, USA), operating in reflectron positive ion mode. Ions, 
formed by a pulsed UV laser (λ = 337 nm) beam were accelerated to 20 keV. Instru-
mental set up was: mirror ratio 1.12; grid voltage 72%; extraction delay time 150 nsec; 
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grid wire 0.05%. External mass calibration was performed by the Calibration Mixture 
2 of SequazymeTM Peptide Mass Standards Kit. Sample deposition was performed us-
ing alpha-cyano-4-hydroxycinnamic acid (CHCA, Sigma-Aldrich, St. Louis, MO, 
USA) in a 50% ACN/0.05% TFA (v/v) as matrix solution.  
MALDI-TOF data files were exported as .txt files and processed with mMass open 
source software (Strohalm et al., 2008). Spectra have been denoised (precision 15, rela-
tive offset 25, arbitrary units) and smoothed (Savitzky–Golay filtering, m/z 0.15) be-
fore manual peak picking (threshold set S/N=3). 
The peptides were fragmented using an Ultraflex Extreme TOF-TOF instrument 
(Bruker Daltonics, Bremen, Germany) equipped with an Nd:YAG laser (λ=355nm). 
Fragmentation spectra were processed using flexAnalysis v3.3 software and a peaks 
list was generated after baseline subtraction using Snap as peaks detection algorithm. 
Peptides identification was obtained using Mascot v2.3 (Matrix Science, London, UK) 
and MS-Tag (UCSF, CA, USA) search engines. Search parameters were set as follow: 
database, NCBInr.2013.6.17; enzyme, no enzyme; taxonomy, Homo sapiens; precursor 
tolerance, 0.3 Da, fragment tolerance, 0.6 Da; variable modifications: acetyl (N-term); 
deamidated (N/Q); Gln->pyro-Glu (N-term Q/E) and oxidation (M/W/P). 
 
2.1.4. ELISA assay 
ELISA assays specific for C4b and C3b (MyBiosource kits) was used to analyzed in 
total 10 FAP, 8 Adenoma, 36 CRC patients and 22 health subjects. 
The C4b assay kit (MBS700316) is based on the quantitative sandwich enzyme immu-
noassay technique. Briefly, the microplate was pre-coated with an antibody specific for 
C4b and the standard and sample were added in each well, so any C4b present was 
bound to the immobilized antibody. A biotin-coniugated antibody specific for C4b was 
added into the well, followed by an avidin-coniugated Horseradish Peroxidase (HRP). 
Before each step a wash was done in order to remove any unbound substance. Then, 
the staining reaction was blocked and the optical density (OD) was measured 
spectrophotometrically at λ=450 nm in a microplate reader.  
The C3b assay kit (MBS745371) applies the competitive enzyme immunoassay tech-
nique using a monoclonal anti C3b antibody and C3b HRP -conjugated. The sample 
and standards in this case, were incubated together with C3b HRP conjugated in 
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precoated plate. The optical density was inversely proportional to the C3b concentra-
tion since C3b from the sample and C3b HRP-coniugated compete for the anti-C3b an-
tibody binding site.  
The standard curve of both assay was created using the “Curve Expert 1.4” software 
and it was plotted relating the intensity of the color (OD) to the concentration of stand-
ards. The C4b and C3b concentrations in each sample were interpolated from this 
standard curve. 
 
2.1.5.  Statistical analysis  
The statistical analysis for MALDI dataset was performed using MetaboAnalyst 2.0 
software. The peak list was normalized by sample median intensity and log trans-
formed. Univariate analysis (one-way ANOVA, t-test, fold change, and Volcano plot) 
and multivariate analysis (Cluster Analysis (CA), Partial Least Square-Discriminant 
Analysis (PLS-DA) and Random Forest (RF)) were used. The Box plot was performed 
by GraphPad Prism 5 software. 
 
 
2.2. WHOLE EXOME SEQUENCING 
2.2.1. Genomic DNA extraction 
Genomic DNA of 4 unresolved FAP patients was isolated from peripheral blood lym-
phocytes using QIAamp DNA Mini Kit (Qiagen) following the manufactures’ user 
guide. 
 
2.2.2. Next Generation Sequencing analysis 
The genomic DNA samples of the four unresolved FAP patients was sent to the Labor-
atory of Prof. Paolo Fortina (Kimmel Cancer Center, Philadelphia) for the analysis. 
The whole exome sequencing considers an enrichment step in which are selected only 
the  exome regions. The enrichment step was performed with SureSelect Human All 
Exon Target Enrichment System (Agilent Technologies). The genomic DNA (3µg) of 
four unresolved FAP patients was sheared into short fragments of about 300 bp. These 
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DNA fragments were hybridized into solution with RNA oligonucleotides, to specific 
target approximately 38 Mb of the human genome (1.22% of the genome) covering 
~18,000 genes. Non selected regions were washed off and the selected fragments were 
eluted to create a library enriched for the protein coding sequences. Adapter sequences 
were ligated to DNA, before or after enrichment step, to lead the sequencing process 
(Figure 8). 
 
Figure 8: Exons library production. 
 
WES analysis was performed by Sequencing by Oligonucleotide Ligation and Detec-
tion (SOLiD 4) instrument (Life Technologies Foster City, CA) with 80X coverage. 
The SOLiD system is a massively parallel DNA sequencer based on sequencing-by-
ligation. The method consist of an emulsion PCR on glass beads. The beads are added 
in excess so that each bead links only one fragment and only the beads with the com-
plementary adapter oligos are used. Briefly, after hybridization step 500 picomoles of 
the enriched exome library were used for the emulsion PCR in which the mineral oil 
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allows the formation of micelle, each of them acts like a single compartment. The sin-
gle DNA molecules produced on the glass beads are then deposited onto a glass slide 
(Figure 9). 
 
Figure 9: Emulsion PCR done on glass beads. 
 
A universal primer is annealed and the selective hybridization and ligation of comple-
mentary probes occurs to establish the sequence. The universal primer recognizes the 
adapter sequence; DNA octamers (having a fluorescent dimer) bind DNA and are 
ligated. Afterwards, the last three bases are cut and a new step of hybridization occurs 
(Figure 10).  
 
 
Figure 10: Sequencing-by-ligation. 
 
Paired-end sequencing was performed. In this method, two ends of the same DNA 
fragment are sequenced in opposite directions which spans an inserted sequence of 
~180 bp. The two sequenced fragments are 50 bp (F3 tag) and 35 bp (F5 tag). When 
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mapped back to the genome, the two-paired sequences should map to the same region 
and separated by a distance of the inserted fragment. 
 
2.2.3. WES data analysis  
The SHRiMP software was used for the data analysis, following three distinct steps. 
First, the color space reads were mapped to the hg19/GRCh37 Reference Genome 
(http://genome.ucsc.edu/) using an iterative mapping approach. The sequence coverage 
was determined as the proportion of targeted regions that was covered by at least one 
unique aligned read. Bases that aligned to the genome, but not to the targeted regions 
were not considered for further analysis. Additionally, only regions that had a coverage 
higher than 8X were considered for further analysis. Over 90% of the targeted exome 
regions had at least 20X depth of coverage in each sample. The second step of the 
bioinformatic screening was to identify genomic variants including SNPs and small in-
sertion deletion variants (indels). The third step of the analysis included the interpreta-
tion of the data obtained.  
 
2.2.4. First elaboration of the data 
Variants were identified using the Genome Analysis Toolkit HaplotypeCaller.  
Resulting variants were annotated using ANNOVAR and filtered considering the fol-
lowing criteria (Filter a): 
1. Non synonymous SNVs  
2. Not included in dbSNPs 
3. At least 5% variant allele frequency 
4. At least 20X coverage. 
 
2.2.5. Second elaboration of the data 
Variants were identified using a custom script.  
ANNOVAR software was used to provide genomic and functional annotation of the 
variants found.  
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We filtered the variants considering the criteria discussed before (Filter a) and the fol-
lowing more stringent criteria (Filter b):  
1. Non synonymous SNVs 
2. Not included in dbSNPs 
3. At least 5% variant allele frequency 
4. At least 50X coverage 
5. Statistical significance p-value threshold of 10-9. 
 
2.2.6. PCR and Sanger sequencing 
The primers were drawn with Primer 3 plus software and validated with UCSC Ge-
nome Bioinformatics database (Table 1 and 2). 
For NBPF16 gene it was not possible to found primers specific for the region of inter-
est showing only one amplification product, therefore they were manually drew. One 
common reverse (rw) primer and 2 forward (fw) primers were used: one specific for 
wild-type (wt) allele and one specific for mutated (mut) allele. The 2 forward primers 
differ for the last base in 3’ end of the sequence (Table 2, in bold). Using this strategy, 
if a subject is wild-type has the band only with the couple wt-fw + rw. If a subject pre-
sents the mutation in homozygous state has the band only with the couple mut-fw + rw, 
whereas if a subject has the mutation in heterozygous state has the band with both cou-
ples of primers. The PCR reactions were performed with GoTaq DNa Polymerase 
(Promega). 
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Gene Protein Variant Primer Forward (fw) Primer Reverse (rw) 
KMT2C Y816_I817delinsX TCCCCACATGAGGAAAGTAT AAAAAGTTGCCATCCACACC 
PABPC1 E156fs GAAATAGGAACTGTGCAGTAATGG CTTAAAATGAATGGATTTGGAATTA 
PRSS3 K152Q TCTCTTCCTGATCCTCACAGC AGCCTCCCTCATTTCCCAAT 
SARM1 S182fs; 183_184del CTGTCCCCTTCCACTTTCAC CTGCGCGCTTCTCTACCAT 
CDC27 V107delinsIV GAGGGATGAAGGAAGGAAGG TGGAAATGCTTTTCTGACAGTT 
MUC16 N13088D CCGTCCTTCTCTCAGCAATC CAGGCAGGAAGTGTGACCTC 
MED12L 2066_2095del CCCTCAAAAGGACGAATGAG  CATGAACAATGCAACCTGCT 
FADS6 P6delinsPMEPTEP CAGAGGAGCCAGGGTGTCT CAAGGCGAAGAGGCTGAG 
VSIG10L A859fs CAAGGATAGCCAGGCATTTT GGGTCCAACCCTCAGTCATA 
GRIA3 G127fs AAGTTGCAGCAAAGGACCAT CAGAGCAGGTGCCTCTTCTTA 
ANAPC1 Q465X CCCATACAGGTTGTTGCATGT TCCCAATCTGAGCAAATTAACA 
CDC27 
L254X; L212X TGAAAACTACAAAGAATGATCTGAA CCCCTGTTTCCACAGTGATT 
K169X AAGGCCTATTTCCTGTTTCCA GAAAATTTCTACCAAGTCATTCACAA 
L155X; L144X CAGGTTTTGGGGTTTGTAGC TGATTCTTGAAACATACCGAAGA 
KMT2C R904X AGATTTTTAAGTTGTGGAGTATACGTT GCCTCACCCCAGGTAATACA 
VEGFC X420L TTCCAGTCTGAAATTTAAAAACACA TTTGTTAGCATGGACCCACA 
Table 1: The primers used to check variants selected by WES analysis data. 
 
Gene Protein Variant 
Primer Forward wild-type (fw-
wt) Primer Reverse 
Primer Forward mutated (fw-
mut) 
NBPF16 V646L TATCAGCTTCGCCCTTTACG CCTATGTCTGGGCTTCCAAA TATCAGCTTCGCCCTTTACT 
Table 2: The primers for the variant in NBPF16 gene. The forward primers differ for the last base 
at 3’ end of the sequence (in bold) and are specific for wild-type allele or mutated allele. 
 
The PCR product was purified using Illustra ExoProStar kit (GE Healthcare) that con-
tains a mix of Illustra Alkaline Phosphatase and Exonuclease A, that remove unincor-
porated primers and nucleotides derived from the amplification reactions step.  
The sequence reaction was performed with the BigDye Terminator v1.1 Cycle Se-
quencing Kit (Applied Biosystem). Afterwards, the sequences were purified with Eth-
anol/EDTA precipitation protocol and subjected to electrophoresis using the AB3130 
XL Genetic Analyzers instrument (Applied Biosystem).  
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3. RESULTS 
3.1. MUTATED FAP PEPTIDOME 
3.1.1. MALDI-TOF analysis of plasma samples 
Plasma samples of FAP patients (n=13), healthy subjects (n=38), adenoma patients 
(n=26) and CRC patients (n=58) were analyzed (Table 3). For CRC patients, the TNM 
(Tumour, Lymph Nodes, Metastasis) cancer classification system allowed the sub-
grouping in early CRC (TNM staging I and II, n=29) and late CRC (TNM staging III 
and IV, n=29). Taking into account that FAP is a hereditary form of cancer character-
ized by an early onset of the pathology, the average age of FAP patients considered, 
resulted lower than the one of adenoma and CRC patients.  
 
 
The clinical information collected from each FAP patient is reported in details in Table 
4. Among the patients recruited, 7 were probands and 6 were patients, first or second 
degree relatives of these probands. Three FAP patients showed Gardner variant charac-
terized by extra intestinal lesions such as cutaneous lesions, osteomas and dental ab-
normalities (Half et al., 2009).  
  
 Control FAP Adenoma Early CRC Late CRC 
N 38 13 26 29 29 
Gender M:F 20:18 07:06 14:12 18:11 18:11 
Average age (years) 55 31 66 71 67 
Range (years) 23-78 18-52 41-80 49-85 46-85 
Table 3 Gender and age summary of controls subjects, FAP, adenoma, and early and late CRC patients 
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For each patient, two spots of sample were analyzed by MALDI-TOF in order to re-
duce the instrumental variability. The spectra were acquired in the mass range 900-
3000 m/z and the spectra signal was averaged to give a single spectrum for each sam-
ple and processed as previously described in the manual peaks picking procedure (Par-
agraph 2.1.3). A peaks list of 91 ionic species (m/z) and their relative signal intensities 
was obtained and subjected to statistical analysis.  
For each specific group, the spectra obtained by MALDI-TOF are reported in Figure 
11, where it is possible to observe the different intensity of the ionic species present in 
the groups considered. For instance, the spectra in Figure 11 ( panel a and b) show a 
clear discrepancy in the peptides abundance between control subjects (panel a) and 
FAP patients (panel b). The ionic species at m/z 1896.03 and 2021.10 showed a higher 
intensity in FAP patients than in the control subjects. On the contrary, in the controls 
the most intense signal was detected at m/z 1060.56. Quite different patterns were ob-
served in adenoma and in the two groups of CRC patients’ spectra (Figure 11, panel c, 
d, e), where the most intense signals were represented by the ionic species at m/z 
1211.65, 1449.81, and 1855.86. These data suggest a possible correlation between the 
observed peptide profiles and the pathological state. However, the spectra from CRC 
patients stage I-II (Figure 11, panel d) and CRC patients stage III-IV (Figure 11, panel 
Patient Family Proband relative 
Age 
(y) Surgery 
Extraintestinal  
manifestation 
Status of APC or 
MutYH gene Sex 
FAP1* 1 Proband 50 Proctocolectomy Pulmonary nodels APC: p.Y935X M 
FAP2 1 Daughter 19 Rectum resec-tion none APC: p.Y935X F 
FAP42 1 Son 24 Rectum  resection none APC: p.Y935X M 
FAP13* 9 Proband 37 Proctocolectomy Osteomas and desmoids APC: p.I1516EfsX9 F 
FAP17* 10 Proband 22 No available none APC: Dup 4-5 F 
FAP19 10 Second  cousin 35 Colectomy none APC: Dup 4-5 M 
FAP20 10 Second  cousin 26 Proctocolectomy 
Mandibular ostemas and 
renal cancer APC: Dup 4-5 M 
FAP35* 14 Proband 18 Total  proctocoletomy none APC: p.S1436IfsX37 M 
FAP26* 15 Proband 52 Total colectomy Abdominal desmoids APC: p.P1993PfsX50 F 
FAP27 15 Daughter  No available none APC: p.P1993PfsX50 F 
FAP24* 16 Proband 30 Proctocolectomy none APC: p.S905KfsX7 M 
FAP25 16 Father 32 Proctocolectomy none APC: p.S905KfsX7 M 
FAP37* 18 Proband  No available none MYH: c.1105delC F 
Table 4: The summary of the clinical information belonging to each mutated FAP patient.  
*: proband; m: male; f: female; in bold: Gardner phenotype. 
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e) resulted very similar between them. These results are in accordance with the data al-
ready published in literature (Zhu et al., 2013) and a possible explanation of this analo-
gy could be that the peptide profile is not subjected to further alteration during CRC 
progression. 
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Figure 11: The MALDI-TOF spectra of control subjects (panel a), FAP patients (panel b), adeno-
ma patients (panel c), stage I-II CRC patients (panel d) and stage III-IV CRC patients (panel e).  
a.i.: arbitrary units. 
 
a 
b 
e 
d 
c 
39 
 
3.1.2.  Statistical analysis 
The peaks list obtained by MALDI data was subjected to statistical analysis. Both 
univariate and multivariate analysis techniques have been considered in order to 
choose ionic species with higher variance among groups. On the total of 91 ionic spe-
cies detected, 50 resulted statistically significant at the ANOVA test (p value <0.05). 
First, a preliminary hierarchical clustering analysis among all the groups of study (con-
trols subjects, FAP, adenoma, early CRC and late CRC patients) was performed. As 
represented in Figure 12, a higher dispersion among adenoma, early CRC and late 
CRC patients was found. In particular, adenoma patients were localized, some near 
CRC patients and other near the controls subjects. However, it was not possible to val-
idate this clustering based on any known features (e.g. adenoma histotype, adenoma 
grading, CRC RAS mutational state). For this reason the early and late CRC were 
merged in a unique group called CRC. 
 
 
Figure 12 The heatmap of the clustering analysis (Euclidean distance and Ward algorithm) of con-
trol subjects, FAP, adenoma, early CRC (stage I-II) and late CRC (stage III-IV) patients. 
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Therefore, a different approach was considered and another hierarchical cluster analy-
sis between FAP patients versus control subjects, adenoma patients and the two groups 
of CRC patients was performed. Using this different statistical strategy, it was possible 
to obtain a clear distinction among FAP patients and the other groups considered (Fig-
ure 13, 14 and 15). Indeed, the FAP patients showed a good classification compared to 
the controls and the adenoma patients. However, some CRC patients resulted to be er-
roneously clustered with FAP patients, due to the similar intensity profile of few ionic 
species.  
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Figure 13: The heatmap of clustering analysis (Pearson distance and Ward algorithm) of FAP pa-
tients versus control subjects. 
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Figure 144: The heatmap of clustering analysis (Pearson distance and Ward algorithm) of FAP 
patients versus adenoma patients. 
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Figure 15: The heatmap of clustering analysis (Pearson distance and Ward algorithm) of FAP pa-
tients versus CRC patients. 
 
On the contrary, considering more robust statistical methods, such as Volcano plot 
(univariate analysis), RF and PLS-DA (multivariate analysis), this overlap between 
FAP and CRC patients did not occur. Using these tests to compare FAP patients versus 
control subjects, adenoma patients and CRC patients respectively, three statistically 
significant subsets of 18, 40 and 17 m/z were obtained. In total, 45 ionic positive spe-
cies were found, 29 of them showing a fold-change >2 in all the three statistical tests 
(Table 5).  
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m/z Controls /FAP 
Adenoma/ 
FAP 
CRC/ 
FAP ID peptide Sequence 
904.46 3.44 0.16 0.09 Des-Arg bradykinin RPPGFSPF 
1060.57 6.92 0.21 0.09 Bradykinin RPPGFSPFR 
1076.56 2.73 0.18 0.14 Oxidized bradykinin RPPGFSPFR 
2209.07 2.04 0.16 0.14 Kininogen fragment KHNLGHGHKHERDQGHGHQ 
2365.16 1.08 0.16 0.20 Kininogen HMW fragment KHNLGHGHKHERDQGHGHQR 
2021.10 0.08 0.10 0.01 C3f SSKITHRIHWESASLLR 
1035.58 0.42 1.60 1.99 C3f fragment THRIHWESA 
1136.57 0.46 2.42 4.61 C3f fragment THRIHWESA 
1211.66 2.57 9.29 2.98 C3f fragment IHWESASLLR 
1249.62 1.13 3.75 3.20 C3f fragment ITHRIHWESA 
1367.76 0.15 0.61 0.18 C3f fragment RIHWESASLLR 
1605.86 0.10 0.37 0.10 C3f fragment THRIHWESASLLR 
1718.99 0.13 0.61 0.08 C3f fragment ITHRIHWESASLLR 
1777.97 0.14 0.36 0.11 C3f fragment SKITHRIHWESASLL 
1865.01 0.10 0.26 0.04 C3f fragment SSKITHRIHWESASLL 
1855.85 0.08 0.51 3.92 C3c SEETKENEGFTVTAEGK 
1896.03 0.04 0.04 0.02 C4A/B precursor  fragments  NGFKSHALQLNNRQIR 
1154.69 0.77 3.14 2.29 C4A/B fragment LQLNNRQIR 
1225.71 0.97 13.76 17.79 C4A/B fragment ALQLNNRQIR 
1327.76 0.57 1.33 1.06 C4A/B fragment FKSHALQLNNR 
1436.73 2.41 9.13 6.06 C4A/B fragment GLEEELQFSLGSK 
1449.79 1.48 11.37 11.64 C4A/B deamidated  fragment SHALQLNNRQIR 
1498.90 1.94 0.51 0.48 C4A/B  fragment NGFKSHALQLNNR 
1499.78 147.56 68.78 79.36 C4A/B fragment SHALQLNNRQIR 
2861.34 0.58 0.16 0.28 Fibrinogen. alpha chain QGVNDNEEGFFSARGH 
1606.86 11.78 61.36 81.10 Fibrinogen. alpha chain fragment SSHHPGIAEFPSRGK 
1552.68 2.30 6.04 14.06 Fibrinopeptide B QGVNDNEEGFFSAR 
1746.75 1.93 0.31 0.27 Fibrinogen. beta chain fragment SSHHPGIAEFPSRGK 
2167.08 0.83 0.21 0.18 Pyro-glu ITIH4 fragment QLGLPGPPDVPDHAAYHPFR 
Table 5: The median intensity ratio (controls vs FAP; adenoma vs FAP and CRC vs FAP) of sta-
tistically significant m/z and their relative identification and sequence. In bold the distinctive pep-
tides of FAP patients are reported. 
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3.1.3. Peptide identification 
Fifty peptides out of the 91 present in the peaks list were identified by MS/MS experi-
ments (Table 6).  
 
Peptide m/z Sequence 
Protein: P01024, Complement C3 
C3c 1855.9 SEETKENEGFTVTAEGK 
C3f 2021.1 SSKITHRIHWESASLLR 
C3f fragments 1035.6 THRIHWESA 
 1098.6 HWESASLLR 
 1136.6 THRIHWESA 
 1211.7 IHWESASLLR 
 1249.6 ITHRIHWESA 
 1367.8 RIHWESASLLR 
 1377.8 KITHRIHWESA 
 1465.1 SKITHRIHWESA 
 1551.8 SKITHRIHWESA 
 1605.9 THRIHWESASLLR 
 1719.0 ITHRIHWESASLLR 
 1778.0 SKITHRIHWESASLL 
 1865.0 SSKITHRIHWESASLL 
Protein: P01042, Kininogen HMW 
Bradikinin 1060.6 RPPGFSPFR 
 1076.6 RPPGFSPFR 
Des-Arg Bradikinin 904.5 RPPGFSPF 
 1348.7 RHDWGHEKQR 
Kininogen-1 light chain 2365.2 KHNLGHGHKHERDQGHGHQR 
 2209.1 KHNLGHGHKHERDQGHGHQ 
Protein: P02671, Fibrinogen alpha chain 
Alpha chain 2861.3 MADEAGSEADHEGTHSTKRGHAKSRPV 
 2659.3 DEAGSEADHEGTHSTKRGHAKSRPV 
 2681.2 SSSYSKQFTSSTSYNRGDSTFESK 
 1606.9 SSHHPGIAEFPSRGK 
Fibrinopeptide A 1536.7 ADSGEGDFLAEGGGVR 
 1616.7 ADSGEGDFLAEGGGVR 
Protein: P02675, Fibrinogen beta chain 
Beta chain 2235.2 KREEAPSLRPAPPPISGGGYR 
 2484.2 QGVNDNEEGFFSARGHRPLDKK 
 2356.1 QGVNDNEEGFFSARGHRPLDK 
 2228.0 QGVNDNEEGFFSARGHRPLD 
 1999.9 QGVNDNEEGFFSARGHRP 
 1746.8 QGVNDNEEGFFSARGH 
Fibrinopeptide B 1552.7 QGVNDNEEGFFSAR 
Protein: P08697, Alpha-2 antiplasmin  
Propeptide 1285.7 MEPLGRQLTSGP 
Protein: P0C0L4/5, Complement C4A/B 
C4 b 1896.0 NGFKSHALQLNNRQIR 
 1897.0 NGFKSHALQLNNRQIR 
 1891.0 GLEEELQFSLGSKINVK 
C4 b fragments 1499.8 NGFKSHALQLNNR 
 1052.6 SHALQLNNR 
 1154.7 LQLNNRQIR 
 1225.7 ALQLNNRQIR 
 1327.8 FKSHALQLNNR 
 1384.7 GFKSHALQLNNR 
 1436.7 GLEEELQFSLGSK 
 1449.8 SHALQLNNRQIR 
 1498.9 NGFKSHALQLNNR 
 1782.0 GFKSHALQLNNRQIR 
Protein: P10909, Clusterin 
Beta chain peptide 1530.9 RPHFFFPKSRIV 
Protein: Q14624, ITIH4  
Proline-rich (PRR) peptide 1675.8 GPPDVPDHAAYHPFR 
Table 6: The peptides identified among the total ones present in the peaks’ list. 
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The Table 5 reports the identification of 29 peptides identified through the previously 
described statistical analysis. The peptides are mainly fragments of circulating pro-
teins, such as: Kininogen, Fibrinogen, Complement 3, Complement 4A/B and Inter-
Alpha-Trypsin Inhibitor Heavy Chain. Most of the observed peptides belong to few 
precursor peptides subjected to extensive ladder-like truncations. For instance, several 
fragments derive from the peptides identified at m/z 2021.10 and 1896.03. Twelve of 
the identified m/z had a distinctive signature in FAP patients (Table 5, in bold) show-
ing the same trend in these patients but not in the other groups. These peptides were: 
C3f (at m/z 2021.10) and its fragments (at m/z 1211.66; 1367.76; 1605.86; 1718.99; 
1777.96; 1865.01); the C4A/B precursor fragments (at m/z 1896.03) and its fragments 
(at m/z 1436.73; 1499.78); the Fibrinopeptide B (at m/z 1552.67) and Fibrinogen alpha 
chain peptide (at m/z 1606.86). 
The C3f is a 17 amino acids peptide having a mass-average of 2020 Da and derives 
from the cleavage of C3b into iC3b done by the complement Factors I and H (Ishida et 
al., 2008). The m/z 2021.10 intensity (C3f) was higher in FAP patients and was found 
to be significantly decreased in the controls, adenomas and CRC patients (Figure 16, 
panel a). Additionally, C3f intensity was statistically significant different between FAP 
probands and FAP relatives, highlighting the effect of genetic mutation in the pheno-
type. The same tendency was observed for the intensity of its fragment at m/z 1367.76, 
1605.86, 1718.99, 1777.89 and1865.01 (Figure 17, panel a). On the contrary, only one 
C3f fragment intensity (at m/z 1211.66) was decreased in FAP patients and not in the 
other groups. C3f fragments at m/z 1035.57 and 1136.57 were higher in all patient 
groups, whereas m/z 1249.62 was high only in adenoma and CRC patients. 
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Figure 16: Box plot of ionic species significantly different among the samples of control subjects, 
FAP patients, adenoma and CRC patients. (Tukey’s outliers are reported; *p<0.05; **p<0.01; *** 
p<0.001). 
 
The m/z 1855.85 intensity (Complement C3c) was increased in FAP and in adenoma 
and it was found even higher in CRC patients. 
The C4A/B fragment peptide at m/z 1896.03 was significantly increased in FAP pa-
tients (Figure 16, panel b). The intensity of the m/z 1436.73 and 1499.78 fragments 
were decreased in FAP patients whereas both of them were increased in adenoma and 
CRC patients (Figure 17, panel b). The C4A/B fragments derived from the ionic spe-
cies at m/z 1896.03 (i.e. those at m/z 1154.68, 1225.71, 1327.76 and 1449.79) were 
higher in adenoma and CRC patients, instead the m/z 1498.89 was lower in these 
groups.  
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Figure 17: The percentage of C3f intensity (panel a) and C4A/B (panel b) fragments relative to 
their total amount in FAP, adenoma and CRC patients and controls groups. The percentage of 
each m/z species was calculated dividing the single intensity by the sum of their total intensity. 
 
The intensity of ionic species at m/z 1552.67 (Fibrinopeptide B) and 1606.86 (the pep-
tide of alpha chain fragment of Fibrinogen) were found to be higher in adenoma and 
CRC patients than in controls and FAP patients.  
In order to understand which peptides could mark the switch between adenoma and 
malignant carcinoma, they were chosen only the ionic species showing an increase or 
decrease trend among FAP, adenoma and CRC patients and that were statistically dif-
ferent in all kind of comparisons. Using this criteria, it was possible to select four ionic 
species with a decreasing tendency: C3f peptide (at m/z 2021.10) and its fragments at 
m/z 1367.76, 1718.99 and 1865.01. These four peptides were differently present 
among the patients’ groups considered, although they showed a similar intensity both 
in the control subjects and in the CRC patients (Figure 16 and 18).  
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Figure 18: Box plot results about ANOVA significant C3f fragments with decrease trend among 
FAP, Adenoma and CRC patients. (Tukey’s outliers are reported; *p<0.05; **p<0.01; *** 
p<0.001) 
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3.1.4. C3 and C4 quantification by ELISA  
In order to understand if the observed changes in the peptides derived from comple-
ment proteins were related to changes in the precursor proteins C3b and C4b levels, the 
ELISA assay was performed. There were no differences in the quantity of C4b among 
the groups samples (Figure 19, panel b). Instead, the quantity of C3b between control 
group and CRC patients was different as well as between FAP and CRC patients; 
whereas between FAP patients and control group no significant expression changes 
were detected (Figure 19, panel a). 
 
Figure 19: Box plot showing plasma amount of C3b (a) and C4b (b) in FAP, adenoma, CRC pa-
tients and control subjects. Highly significant C3b concentration changes were detectable only be-
tween CRC patients and healthy subjects and between FAP and CRC patients (a). (Tukey’s out-
liers are reported; *p<0.05; **p<0.01; *** p<0.001). 
 
3.2. UNRESOLVED FAP PEPTIDOME 
The plasma sample of the four unresolved FAP patients was analysed and a peaks list 
of 92 ionic species, (m/z) representing plasmatic peptide and their relative signal inten-
sities, was obtained. In this study, the attention was focused on the ionic species de-
scribed in the previous paragraphs to be characteristic of mutated FAP patients. In par-
ticular, the C3f fragment at m/z 2021.10 and C4A/B precursor fragment at m/z 1896.03 
in unresolved FAP patients have characteristic similar to the other groups (control sub-
jects, adenoma patients and CRC patients) but not to the mutated FAP patients (Figure 
20). These data further indicate and sustain the differences between unresolved and 
mutated FAP groups. 
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Figure 19: Box plot of ionic species significantly different among the samples of control subjects, 
mutated and unresolved FAP patients, adenoma and CRC patients. (Tukey’s outliers are report-
ed; *** p<0.001). 
 
3.3. UNRESOLVED FAP WHOLE EXOME SEQUENC-
ING 
In order to be able to identify a possible specific genetic pattern for unresolved FAP, a 
WES analysis by SOLiD4 instrument was performed. The clinical information collect-
ed from each unresolved FAP patient are reported in details in the Table 7.  
 
Patient Age (y) Surgery Extra-intestinal Manifestations Sex 
FAP179* 68 Right hemicolectomy Melanoma m 
FAP204* 54 Proctocolectomy none m 
FAP207* 25 Subtotal colectomy Osteomas, lipoma and supernumerary teeth m 
FAP211* 61 Subtotal colectomy none m 
Table 7: Summary of the clinical information of each unresolved FAP patient.  
*: proband; m: male; f: female; bold: Gardner  phenotype. 
 
3.3.1. Filtered variants confirmation approach 
The reads were mapped to the hg19/GRCh37 Reference Genome and the variants were 
identified as described previously in the paragraph first elaboration of the data in the 
materials and methods section (Paragraph 2.2.4) and filtered using filter a. Using these 
criteria and applying VCF tools program (vcftools is a suite of functions to use on ge-
netic variation data in the form of VCF and BCF files; the tools provided is used main-
ly to summarize data, run calculations on data, filter out data, and convert data into 
other useful file formats) it was possible to select 16 variants present in all unresolved 
FAP patients (Table 8).  
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Gene Name Exonic  Function 
Reference sequence:coding sequence variant:protein 
variant 
Sanger  
validation 
LOC440563 
Heterogeneous Nuclear 
Ribonucleoprotein C-Like2, 
pseudogene 
nonsynonymous 
SNV NM_001136561:c.A764G:p.D255G n.p. 
LOC440563 Heterogeneous Nuclear Ribonucleoprotein C-Like2 
nonsynonymous 
SNV NM_001136561:c.G763T:p.D255Y n.p. 
NBPF16 Neuroblastoma Breakpoint Family, Member 16 
nonsynonymous 
SNV NM_001102663:c.G1936T:p.V646L wt 
RBMXL1 RNA Binding Motif Pro-tein, X-Linked-Like 1 
frameshift  
deletion NM_019610:c.1delA:p.M1fs n.p. 
MED12L Mediator complex subunit 12-like 
nonframeshift 
deletion NM_053002:c.6198_6284del:p.2066_2095del wt 
KMT2C 
Histone methyltransferase 
gene mixed-lineage leuke-
mia 3 (Lysine  specific 
Methyiltransferase 2C) 
stopgain SNV NM_170606:c.2447dupA:p.Y816_I817delinsX wt 
PABPC1 Poly(A) binding protein, cytoplasmic 1 
frameshift  
insertion NM_002568:c.467_468insG:p.E156fs wt 
PRSS3 Protease, serine, 3, meso-trypsinogen 
nonsynonymous 
SNV NM_001197098:c.A454C:p.K152Q wt 
SARM1 Sterile alpha and TIR motif containing 1 
frameshift  
insertion 
NM_015077:c.544_545insGC:p.S182fs wt 
NM_015077:c.549_550del:p.183_184del wt 
CDC27 
(APC3) 
Cell division cycle 27 (ana-
phase promoting complex 
3) 
nonframeshift 
insertion NM_001114091:c.318_319insATC:p.V107delinsIV wt 
FADS6 Fatty acid desaturase 6 nonframeshift insertion 
NM_178128:c.17_18insGATGGAACCTACGGAGCC:p.
P6delinsPMEPTEP 
Sequencing 
error or poly-
morphism 
KATNAL2 Katanin p60 subunit A-like 2 
frameshift  
insertion NM_031303:c.850_851insGC:p.E284fs n.p. 
VSIG10L V-set and immunoglobulin domain containing 10 like 
frameshift inser-
tion NM_001163922:c.2576dupC:p.A859fs 
rs397723022 
dbSNV, pre-
sent also in 
healthy con-
trols 
MUC16 
(CA125) 
Mucin 16, cell surface as-
sociated 
nonsynonymous 
SNV NM_024690:c.A39262G:p.N13088D wt 
GRIA3 Glutamate receptor, iono-tropic, AMPA 3 
frameshift  
insertion NM_001256743:c.382dupG:p.G127fs wt 
Table 8: List of 16 common variants obtained with first elaboration of data and filtered with filter 
a. 
SNV: Single Nucleotide Variant; n.p.: not performed; wt: wild-type. 
 
After a careful literature revision, out of the 16 common variants only 7 variants and 6 
genes were described to be involved in cancer development. These genes were: 
KMT2C, PABPC1, PRSS3, SARM1, CDC27 and MUC16. To confirm the selected var-
iants, the Sanger sequencing was performed, but all the 6 genes resulted wild type.  
To further sustain the robustness of this analytical approach, other variants present in 
the NBPF16, MED12, FAD6, VSIG10L and GRIA3 genes were confirmed with other 
methods. 
For the variants in NBPF16 and MED12 genes, the PCR primer design allowed a sim-
ple check of the PCR product on the agarose gel. The unresolved FAP patients present-
ed wild type alleles for both gene variants. 
Concerning NBPF16 gene, a PCR was performed using a common reverse primer and 
two different forward primers, one specific for the wild type allele and the other specif-
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ic for the mutated allele. The forward primers differ from each other for the last base at 
3’ of the sequence. The unresolved FAP patients were wild type for this gene variant, 
indeed, as it is showed in figure 21, only the reverse/wild type forward primers combi-
nation shows the amplification band whereas the reverse/mutated forward primers 
combination did not amplify any band.  
 
Figure 20: NBPF16 gene agarose gel picture. Unresolved FAP patients present only the amplifica-
tion band resulted from the reverse/wild type forward primers combination and no band were de-
tectable from  the reverse + mutated forward primers combination. n:c: negative control; Fw wt: 
wild type forward primer ; Fw mut: mutated forward primer ; arrow: 200bp 
 
Concerning MED12 gene, the PCR product of the wild type has 86 bases more com-
pared to the mutated subject, allowing a clear visualization of the amplified products 
using the agarose gel. As it is showed in figure 22 the unresolved FAP patients were all 
wild type for the MED12 deletion obtained from WES analysis.  
 
Figure 21: MED12 gene agarose gel picture. The wild-type allele has a 346 base pair long band, 
whereas the deleted allele has a 259 base pairs band. Unresolved FAP patients have only the 346 
bp wild type band. p.c. positive control (wt), n:c: negative control; arrow: 300bp. 
 
Sanger sequencing was instead performed for FAD 6, VSIG10L and GRIA3 genes. In 
particular, FAD6 and VSIG10L gene resulted mutated in FAP patients and in the 
healthy controls (n=5). In particular, for the FAD6 gene, the UNIPROT database re-
ported that: “the N-terminus of the sequence BAC04349.1 contains a duplication of the 
repeated MEPTEP sequence. It is unclear whether such duplication is due to a se-
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quencing error or a polymorphism”. Concerning the VSIG10L gene, its variant is pre-
sent in the dbSNPs database (i.e. rs397723022) and, using another software (i.e. Muta-
tion Tasting Prediction software), is considered as a polymorphism. The GRIA3 gene, 
instead, resulted to be wild-type using the Sanger sequencing.  
At this point the variants were re-identified as described in the paragraph of the materi-
als and methods section (the second elaboration of the data) and filtered using filter a.  
First it was taken in consideration the stop loss and the stop gain variants, identifying 
15 common genes and 21 common variants (Table 9).  
 
Gene Name Reference sequence:coding sequence vari-ant:protein variant 
Sanger  
sequencing 
ANAPC1 Anaphase Promoting Complex Subunit 1 NM_022662:c.C1393T:p.Q465X Present also in healthy controls 
ANKRD36 Ankyrin Repeat Domain 36 NM_001164315:c.T4479G:p.Y1493X n.p. 
ANKRD36B Ankyrin Repeat Domain 36B NM_025190:c.T2715G:p.Y905X n.p. 
CCDC144NL Coiled-Coil Domain Containing 144 Fami-ly, N-Terminal Like NM_001004306:c.C533A:p.S178X n.p. 
CDC27 Cell division cycle 27 (anaphase promoting complex 3) 
NM_001114091:c.T761G:p.L254X wt 
NM_001114091:c.T635G:p.L212X wt 
NM_001114091:c.A505T:p.K169X wt 
NM_001114091:c.T464G:p.L155X wt 
NM_001114091:c.T431G:p.L144X wt 
CTBP2 C-Terminal Binding Protein 2 NM_001083914:c.A22T: p.K8X n.p. 
HYDIN Axonemal Central Pair Apparatus Protein NM_001270974:c.C11713T:p.Q3905X n.p. NM_001270974:c.T3052C:p.X1018Q n.p. 
KMT2C 
Histone methyltransferase gene mixed-
lineage leukemia 3 (Lysine  specific 
Methyiltransferase 2C) 
NM_170606:c.C2710T:p.R904X wt 
NCOR1 Nuclear Receptor Corepressor 1 NM_001190438:c.C241T:p.R81X n.p. 
PRAMEF1 PRAME Family Member 1 NM_023013:c.T314A:p.L105X n.p. 
SEC22B SEC22 Vesicle Trafficking Protein Homo-log B (S. Cerevisiae) (Gene/Pseudogene) NM_004892:c.C394T:p.R132X n.p. 
SRGAP2B, 
SRGAP2C, 
SRGAP2D 
SLIT-ROBO Rho GTPase Activating Pro-
tein 2B, 2C, 2D (pseudogene) NM_001271872:c.T1096G:p.X366G n.p. 
TP53TG5 TP53 Target 5 NM_014477:c.G292T:p.E98X n.p. 
VEGFC Vascular Endothelial Growth Factor C NM_005429:c.A1259T:p.X420L wt 
ZNF717 Zinc Finger Protein 717 
NM_001128223:c.A2518T:p.K840X n.p. 
NM_001128223:c.G1957T:p.G653X n.p. 
NM_001128223:c.G1858T:p.E620X n.p. 
Table 9: The list of 21 common stop gain and stop loss variants obtained with the first elaboration 
of data and filtered with filter b. 
n.p.:not performed; wt: wild-type. 
 
Among these, 4 genes (i.e. CDC27, KMT2C, VEGFC, ANAPC1) are known in litera-
ture to be involved in cancer development and in this thesis 8 variants of these genes 
were confirmed by Sanger sequencing. The variants in the CDC27, KMT2C, VEGFC 
genes resulted wild type, whereas the variant in ANAPC1 gene resulted mutated in 
FAP patients and in the health control (n=5). 
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3.3.2. Pathways enrichment approach 
In the case of the four unresolved FAP patients, a different strategy was considered in 
order to identify and select specific disease related genes and variants. The WES data 
were screened for the pathway and not anymore for the genes.  
The variants were identified as described in the second elaboration of data paragraph in 
the materials and methods section and filtered using more stringent filter b. Using these 
criteria it was possible to identify a list of variants for each unresolved FAP patients 
(Table 10). The table shows that one of the patients (FAP179) resulted to have almost 
two times more variants than the others. This discrepancy could be explained in two 
different ways. The first could be that the patient, indeed, presents more variants in his 
genomes compared to the others. The second possibility is that, due to technical rea-
sons, the quality of the DNA extract from this patient was not sufficient to obtain a 
clear and specific read out. 
 
 Total variants Filtered variants Genes 
FAP179 53464 2160 1462 
FAP204 24754 1327 1002 
FAP207 25413 939 718 
FAP211 22779 490 379 
Table 10: Number of variants and genes obtained with the second elaboration of the data and fil-
tered with filter b for each unresolved FAP patients. 
 
From these results, only the variants present in all the patients were selected and 372 
common variants and 285 common genes were identified.  
Considering all the common genes, the hypergeometric distribution (Figure 24) was 
used to perform the pathway enrichment analysis with the PathDIP software 
(http://ophid.utoronto.ca/pathDIP).  
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Figure 22: Hypergeometric distribution was used to gather the unresolved FAP patients common 
genes obtained from WES analysis. 
 
Using this analysis, the O-linked glycans pathway of the mucins resulted to be highly 
enriched. In particular they were identified five common mucin genes related both to 
secreted mucins (e.g. MUC2, MUC5B, MUC6) and to cell surface mucins (e.g. MUC4, 
MUC16). The total number of variants belonging to these genes was 44, however only 
11 of these resulted to be “possibly-probably damaging” using the Polyphen-2 predic-
tion software (Table 11).  
It will be important to further study the identified mucin gene variations in unresolved 
FAP patients, to confirm the possible causative role of these genes in polyposis. 
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gene transcript_ID cDNA_change AA_change Polyphen-v2 Score 
MUC6 NM_005961 C5732T T1911M probably damaging 1 
MUC5B NM_002458 G7051A V2351I probably damaging 0,749 
MUC5B NM_002458 C13211G A4404G probably damaging 0,86 
MUC16 NM_024690 C42148G P14050A probably damaging 0,986 
MUC16 NM_024690 A40697G Q13566R possibly damaging 0,679 
MUC16 NM_024690 C19331T T6444I possibly damaging 0,842 
MUC16 NM_024690 A4200T K1400N possibly damaging 0,614 
MUC4 NM_018406 G7693A D2565N possibly damaging 0,845 
MUC4 NM_018406 C7685A P2562H probably damaging 0,994 
MUC4 NM_018406 A6409G T2137A possibly damaging 0,528 
MUC4 NM_018406 A6344T D2115V probably damaging 0,979 
Table 11: List of possibly-probably pathogenetic variants of mucin genes selected with PolyPhen-
v2 software.  
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4. DISCUSSION  
 
Hereditary factors play a role in around 5–15% of all CRC cases. Colorectal cancer 
caused by highly penetrant mutations, such as those involved in tumor suppression 
genes or the DNA mismatch repair system, include Lynch syndrome, Familial Adeno-
matous Polyposis and MutHY-associated Polyposis. A prompt identification of indi-
viduals with a genetic predisposition to CRC is imperative, as it enables the use of pre-
ventative measures (i.e. the colonoscopy). Periodic examination by colonoscopy has 
been highly effective in reducing CRC-associated mortality in individuals at high risk 
of CRC. Polyposis syndromes are fairly easy to recognize, but some patients might 
have characteristics that overlap with other clinically defined syndromes. It has been 
shown in literature that a comprehensive analysis of the genes known to be associated 
with polyposis syndromes helps to establish the final diagnosis in these patients (Vasen 
et al., 2015). The FAP hallmark is the development of hundreds to thousands of colon 
and rectum adenomas, which confer a near 100% risk of CRC development by age 40, 
in the absence of any medical intervention. APC gene mutations are detected in more 
than 80% of patients with classical FAP and up to 30% of individual with classic poly-
posis but without a detectable APC mutation, may have bilallelic mutations in the 
MutHY gene (Kastrinos and Syngal, 2011).  
In this study four patients, showing at the colonoscopy hundreds adenomatous polyps 
(commensurable to full-blown FAP patients) but not having mutations in APC or 
MutYH genes, were analyzed. In details, these patients were defined as “unresolved 
FAP patients” and their interactome was investigated, considering that they were char-
acterized by a very severe phenotype leading to CRC development. The interactome is 
defined as a biological network including the whole set of direct and indirect molecular 
interactions in a cell. In the -omics era, it is possible to combine genomic and proteo-
mic data to study the biological network of a subject. For example in the study per-
formed by Agostini et al. (Agostini et al., 2015), the authors used the microarray data 
of the responder and not responder rectal cancer patients that had neoadjuvant radio 
chemotherapy before surgery. In order to remove redundant information, using statisti-
cal analysis together with a logistic model, they were able to select 4 genes. Only with 
this network analysis it was be possible to correlate 3 of these genes with another one, 
whereas with other methods they did not come up at all.  
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In this thesis the peptidome and genome data were combined to characterize unre-
solved FAP patient. The first step of this work was to perform a peptidomic analysis of 
the mutated FAP patients. Afterwards, the peptidomic and genomic analysis of unre-
solved FAP patients was done in order to define a specific pattern of these patients.  
Peptidomic data of mutated FAP patients 
In the peptidomic profile of mutated FAP patients, the low molecular weight fraction 
of the blood proteome, derived from the altered tumor protease activity, was taken in 
consideration. This represents, indeed, a promising source of novel human diseases bi-
omarkers. The plasma peptide profile of FAP patients was compared with adenoma pa-
tients, CRC patients and healthy controls, to find a FAP disease specific peptide fin-
gerprint. Twelve ionic species (Table 5, in bold), deriving from circulating peptides, 
showed a peculiar pattern in FAP patients. These peptides can be divided into three dif-
ferent groups: 1) C3f and its fragments; 2) a peptide from C4A/B and its fragments and 
3) any blood clotting proteins. In order to give a prognostic biomarker for FAP pa-
tients, four peptides were selected as possible distinctive key regulators in the switch 
between adenoma and malignant carcinoma. Complement C3f and some of its frag-
ments with a peculiar decrease trend from FAP to adenoma and CRC patients were 
identified. Among the identified peptides, there were mainly fragments belonging to 
the physiological circulating proteins and a group of these peptides are known to be in-
volved in the inflammatory response. Inflammation orchestrates the microenvironment 
around tumors, contributing to the cell proliferation, survival and migration 
(Ungefroren et al., 2011). On the other hand, many cells of the immune system con-
tribute to the cancer control, suppressing cancer growth (Gunn et al., 2012). FAP pa-
tients develop hundreds to thousands of adenomatous polyps that could explain the 
presence of a concomitant altered inflammatory response. The complement system is 
known to be involved in the innate immunity and plays an important role in the surveil-
lance against tumors (Janssen et al., 2005). For decades, the complement has been rec-
ognized as an effector part of the immune system that contributes to the destruction of 
tumor cells. However, recent studies have challenged this paradigm by demonstrating a 
tumor-promoting role for the complement (Pio et al., 2013). Bonavita and collaborators 
(Bonavita et al., 2015) described for the first time that a regulatory component of the 
humoral part of the innate immunity, pentraxin PTX3, acts as an extrinsic 
oncosuppressor gene in mouse and human. There are three distinct pathways of the 
complement activation, all of them joined at the level of the complement component 
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C3 convertase that cleaves C3 to generate C3a and C3b. C3b stimulates the 
opsonization by phagocytic cells and enhances clearance of immune complexes. C3b 
can also take part of C5 convertase (Cook and Botto, 2006). The classical pathway of 
C3 convertase is composed by C2b and C4b, whereas the C5 convertase is composed 
by C3b and C3 convertase (Morgan et al., 2011). In this project, it was possible to de-
scribe a specific pattern, almost unique, for FAP disease characterized by lower levels 
of some of the C4b fragments and an increased level of C3f (Figure 17, panels a and b) 
and some of its ladder-like fragments (Table 5) derived from exoprotease activity. Al-
tered levels of these peptides could be due to different plasma concentration of the C3b 
and C4b precursor proteins, or to different protease activity of Factor I and H, that have 
a central role in the regulation of complement system, or to tissue exoproteases related 
to cancer activity (Villanueva et al., 2006). From the ELISA assay it was possible to 
conclude that C4b and C3b precursors do not increase in FAP patients, suggesting that 
the altered levels of the C4A/B fragment at m/z 1896.03 seem more likely to derive 
from protease activity than from changes in the levels of circulating precursor. Fur-
thermore, the observed increase of C3f was not related to changes in the precursor lev-
els (Figure 19, panel a) and is due to an altered endoprotease activity. The same 
endoproteases determine the increase of the fragment at m/z 1211.66, whereas the in-
crease of ladder-like end fragments could be derived from exoprotease activity.  
Previous studies have reported increased levels of the C3f in the serum of patients af-
fected by several neoplasm such as breast, bladder, thyroid, prostate cancer 
(Villanueva et al., 2006) but not in CRC cancer, where the presence of this peptide is 
decreased (Bedin et al., 2015) (Zhu et al., 2013). Although Ornellas et collaborators 
(Ornellas et al., 2012) found that the peptide C3f at m/z 2021.99 and C4A/B at m/z 
1896.03 showed a low presence in squamous cell carcinoma of the penis patients, 
Profumo and collaborators (Profumo et al., 2013) found that the higher levels of C3f 
present in the serum of women affected by gross cystic disease (a breast benign condi-
tion predisposing to breast cancer) is correlated to the development of breast cancer 
even 20 years before. They explained the higher presence of C3f derived peptides as 
the result of a different concentration of the C3b precursor protein rather than a differ-
ent peptidase activity.  
Complement Factor I is responsible of cleaving both C4b and C3b. Factor I is a serine 
protease that cleaves and inactivates the complement components by preventing the as-
sembly of the C3 and C5 convertase enzymes (GeneCards). Degradation of C4b into 
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the inactive fragments C4c and C4d by Factor I in the presence of the cofactors C4-
binding protein and Factor H, blocks the generation of C3 convertase (UniProt data-
base). The results in this project suggest that the peculiar FAP peptide profile can be a 
consequence of changes in Factor I activity or its cofactors. Okroj and collaborators 
(Okroj et al., 2008) reported that many non small cell lung cancer cell lines secrete the 
soluble complement inhibitors Factor I. Furthermore Riihila and coauthors described 
an overexpression of Factor I in the cutaneous squamous cell carcinoma in vitro 
(Riihila et al., 2015). Bonavita and collaborators (Bonavita et al., 2015) reported that 
the increase complement activation associated to PTX3 deficiency due to the lack of 
recruitment of factor H has a major role in sustaining an exacerbated inflammatory re-
sponse and enhanced carcinogenesis. PTX3 interacts and recruits Factor H by binding 
domain 19-20 and 7 through its N-terminal and glycosylated C-terminal domains re-
spectively, without interfering with Factor H capacity to negatively regulate the com-
plement cascade (Deban et al., 2008). PTX3 gene methylation was detected in CRC 
stages I-IV as well as in the adenoma and this methylation progressively increased 
from normal colon epithelium, to adenoma and to CRC independently of the stage 
(Bonavita et al., 2015). It can be assumed that as the methylation of PTX3 increases, 
the recruitment of factor H and the inactivation of the complement system decrease. 
Taken into account all these results, the combination between the change in the activity 
of Factor I and its cofactors in association with a deregulation of exoprotease activity 
(Villanueva et al., 2006) could explain the FAP peptide pattern that it was observed in 
this work.  
Furthermore, in the ELISA assay it was observed an increase of C3b precursor protein 
in CRC patients compared to FAP patients and control subjects, whereas the peptidome 
showed an opposite trend for C3f and its fragments. However, for a correct analysis of 
this results it is necessary to keep in mind that cancer is a multifactorial disease. In this 
context, the increased levels of C3b in CRC patients probably indicates an activation of 
the complement system and it may be considered just one of these factors. In fact, acti-
vated complement proteins play a role in tumor defense directly through complement-
dependent cytotoxicity and indirectly through antibody-dependent cell-mediated cyto-
toxicity. Neoplastic cells are known to express a wide variety of defenses against com-
plement-mediated attack. The antagonist interaction between the complement and tu-
mor cells, in which the tumor escape is relatively facilitated by the neutralization of the 
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complement attack, underscores the opposing roles of complement in carcinogenesis 
(Rutkowski et al., 2010). 
In conclusion, in this mutated FAP peptidomic study was described for the first time a 
specific plasma peptide pattern that could recognize the FAP patients and, moreover, 
that could predict the malignancy progression allowing the delay of the colonoscopy 
screening and surgery. In CRC patients it was observed an increased level of C3b pre-
cursor but not of the C3f inactivation product and its peptides; in FAP patients it was 
observed the opposite condition, whereas in adenoma patients there was an intermedi-
ate situation. Further studies could elucidate the role of complement system Factor I 
and its cofactor H in FAP pathology progression. In addition, an absolute quantifica-
tion of C3f level in FAP patients should be done in order to define the maximum C3f 
level under which the surgery is necessary. 
Peptidomic and WES data of unresolved FAP patients 
In the study of peptidomic profile of unresolved FAP patients, the analysis was fo-
cused on the ionic species previously described in the results (unresolved FAP pepti-
dome paraghraph of result section) and characteristic of mutated FAP patients. In par-
ticular, it was found that the C3f fragment at m/z 2021.10 and C4A/B precursor frag-
ment at m/z 1896.03 in unresolved FAP patients have characteristic similar to the other 
groups (control subjects, adenoma patients, CRC patients) but not to mutated FAP pa-
tients. These data clearly indicate and sustain the differences between these two 
groups.  
In order to be able to identify a specific pattern for unresolved FAP patients, WES 
analysis was performed. From these datasets, only the variants present in all the pa-
tients were selected, identifying 285 common genes. Considering these common genes, 
the pathway enrichment analysis was performed and the O-linked glycans pathway of 
the mucins was found to be the most represented. O-linked glycosylation is a common 
covalent modification of serine and threonine residues of mammalian glycoproteins 
that occurs in the Golgi apparatus in the eukaryotes. In particular a list of 44 variants 
present in 5 common mucin genes was identified (both secreted mucins MUC2, 
MUC5B, MUC6 and cell surface mucins MUC4, MUC16), 11 of these variants were 
classified as possibly-probably damaging using the Polyphen-2 prediction software. 
Recent studies have demonstrated that the chronic inflammation leads to altered mucin 
expression and glycosylation (Sheng et al., 2012). Furthermore, the expression of mu-
cin genes and the distribution of their product is dramatically altered in certain types of 
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colorectal polyps and neoplasms. These alterations take place through several mecha-
nisms including the aberrant glycosylation of the mucin side chains, the 
immunoreactivity of the mucin core peptide, the deletion of the normally expressed an-
tigens, the expression of the blood-group incompatible antigens and the de novo ap-
pearance of new antigens (Molaei et al., 2010).  
Mucin depletion foci (MDF) are precancerous lesions of the colon, formed by dysplas-
tic crypts lacking mucin production. They have been identified in carcinoma-treated 
rodents and high risk humans colorectal cancers. MDF carry molecular defects proper 
of colon tumor such as APC and CTNNB1 gene mutations. Phenotypically, these lesion 
lead to a defective mucin production due to the lack of MUC2 expression. MUC2 is 
the main mucin produced by the intestinal goblet cells. It has been reported that genet-
ically MUC2-deficent mice develop colitis and CRC spontaneously (Sakai E. et al., 
2011). In humans several studies have showed diminished MUC2 mRNA expression in 
CRC patients (Sakai et al., 2012). Femia A.P. and collaborators have identified MDF 
both in the unsectioned colons of FAP patients and in patients with sporadic CRC, alt-
hough in these at a lower density (Femia et al., 2012). Yoshimi and collaborators 
(Sakai et al., 2012) demonstrated that MDS in FAP patient show a moderate grade of 
dysplasia with a slight nuclear stratification, loss of polarity and Paneth cell metapla-
sia, whereas in sporadic CRC patients MDF change slightly in relation to a low-grade 
dysplasia. They also defined that the inflammatory cell infiltration is a specific histo-
logical feature of MDF. Furthermore, it has been shown that MUC1 and MUC4 can di-
rectly disrupt epithelial cell tight junctions through HER2 activation and promote 
and/or maintain loss of the epithelial cells polarity (Sheng et al., 2012). These results 
indicate that the alteration of MUC2 expression and the lack of the mucus protective 
layer might activate the local inflammation and contribute to MDF progression to a 
more advanced stage of colorectal carcinogenesis in humans.  
Based on the importance of the mucins in the maintenance of a normal mucosa, their 
alterations in the various inflammatory states and cancer, and take in consideration that 
FAP patients present MDS (due to a deficiency in the mucus production), it will be 
important to further study the identified possibly-probably pathogenetic mucin gene 
variations, in unresolved FAP patients, to confirm the possible causative role of these 
genes in polyposis. 
In conclusion, in this study, the combination of high-throughput techniques such as 
MALDI-TOF mass spectrometry together with exome sequencing gave the possibility 
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to define a preliminary pattern for unresolved FAP patients. Peptidomic analysis clear-
ly define a substantial difference between mutated and unresolved FAP patients. Final-
ly WES data suggest that mucin genes are most probably involved in the polyposis 
genesis of the unresolved FAP patients, although to confirm it future analysis of this 
pattern are necessary.  
Clear results to sustain this hypothesis will be definitely fundamental and helpful not 
only to better understand the clinical cases that normally do not show the common 
FAP mutations, but also to be able to define the interactome of the unresolved FAP pa-
tients. Thus, merging peptidomic and WES data, could be useful to study the specific 
physical interactions among molecules (protein-protein interactions) and also describe 
sets of indirect interactions among genes (genetic interactions).  
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